Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients

References

• Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18(8):901–903. doi:10.1210/jcem-18-8-901
   PubMed Web of Science ®Google Scholar
• Lippe B, Frasier SD, Kaplan SA. Use of growth hormone-gel. Arch Dis Child. 1979;54(8):609–613. doi:10.1136/adc.54.8.609
   PubMed Web of Science ®Google Scholar
• De Pedro S, Murillo M, Salinas I, et al. Variability in adherence to rhGH treatment: socioeconomic causes and effect on children’s growth. Growth Horm Igf Res. 2016;26:32–35. doi:10.1016/j.ghir.2015.12.002
   PubMed Web of Science ®Google Scholar
• August GP, Julius JR, Blethen SL. Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National Cooperative Growth Study experience. Pediatrics. 1998;102(Supplement_3):512–516. doi:10.1542/peds.102.S3.512
   PubMedGoogle Scholar
• Bell JJ, Lippe B, Romano AA, Cernich JT, Swinford RD, Moawad D. National cooperative growth study: 25 years of growth hormone data, insights, and lessons for future registries. Pediatr Endocrinol Rev. 2018;16(2):240–255. doi:10.17458/per.vol16.2018.25yearsghdata
   PubMed Web of Science ®Google Scholar
• Child CJ, Zimmermann AG, Chrousos GP, et al. Safety outcomes during pediatric GH therapy: final results from the prospective genesis observational program. J Clin Endocrinol Metab. 2019;104(2):379–389. doi:10.1210/jc.2018-01189
   PubMed Web of Science ®Google Scholar
• Pfaffle R, Bidlingmaier M, Kreitschmann-Andermahr I, et al. Safety and effectiveness of omnitrope r, a biosimilar recombinant human growth hormone: more than 10 years’ experience from the PATRO Children Study. Horm Res Paediatr. 2020;93(3):154–163. doi:10.1159/000508190
   PubMed Web of Science ®Google Scholar
• Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab. 2006;91(6):2047–2054. doi:10.1210/jc.2005-2284
   PubMed Web of Science ®Google Scholar
• Ross JL, Lee PA, Gut R, Germak J. Attaining genetic height potential: analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years. Growth Horm Igf Res. 2015;25(6):286–293. doi:10.1016/j.ghir.2015.08.006
   PubMed Web of Science ®Google Scholar
• Miller BS, Rose SR, Ross JL, et al. Growth hormone dosage associated with change in height standard deviation score over 4 years of treatment by age in pediatric patients with Isolated Growth Hormone Deficiency (IGHD): results from the ANSWER program. Pediatric Academic Societies’ Meeting; 2015; San Diego, CA.
   Google Scholar
• Auer MK, Stieg MR, Hoffmann J, Stalla GK. Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood? Clin Endocrinol (Oxf). 2016;84(6):862–869. doi:10.1111/cen.13030
   PubMed Web of Science ®Google Scholar
• Mancini A, Vergani E, Bruno C, Palladino A, Brunetti A. Relevance of adherence monitoring in adult patients with growth hormone deficiency under replacement therapy: preliminary monocentric data with easypodtm connect. Front Endocrinol. 2019;10:416. doi:10.3389/fendo.2019.00416
   PubMed Web of Science ®Google Scholar
• Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - current status and future considerations. J Clin Endocrinol Metab. 2020;105(6):01. doi:10.1210/clinem/dgz149
   PubMed Web of Science ®Google Scholar
• Strasburger CJ, Vanuga P, Payer J, et al. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. Eur J Endocrinol. 2017;176(3):283–294. doi:10.1530/EJE-16-0748
   PubMed Web of Science ®Google Scholar
• Deal CL, Pastrak A, Silverman LA, Valluri SR, Wajnrajch MP, Cara JF. OR10-06 somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric Phase 3 clinical trial. J Endocr Soc. 2020;4(Supplement_1). doi:10.1210/jendso/bvaa046.1279
   Google Scholar
• Pfizer. OPKO and pfizer announce positive Phase 3 top-line results for somatrogon, an investigational long-acting human growth hormone to treat children with growth hormone deficiency; 2019. Available from: https://www.pfizer.com/news/press-release/press-release-detail/opko_and_pfizer_announce_positive_phase_3_top_line_results_for_somatrogon_an_investigational_long_acting_human_growth_hormone_to_treat_children_with_growth_hormone_deficiency. Accessed February 24, 2022.
   Google Scholar
• Pfizer. Pfizer and OPKO’s once-weekly NGENLA™ (somatrogon) injection receives marketing authorization in European Union for treatment of pediatric growth hormone deficiency; 2022. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-opkos-once-weekly-ngenlatm-somatrogon-injection. Accessed February 26, 2022.
   Google Scholar
• Park B. FDA denies approval of long-acting pediatric growth hormone therapy; 2021. Available from: https://www.empr.com/home/news/drugs-in-The-pipeline/fda-denies-approval-of-long-acting-pediatric-growth-hormone-therapy/. Accessed February 24, 2022.
   Google Scholar
• ClinicalTrials.gov. A research study in children born small and who stayed small. treatment is somapacitan once a week compared to Norditropin® once a day; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03878446. Accessed February 24, 2022.
   Google Scholar
• ClinicalTrials.gov. A research study in children with a low level of hormone to grow. treatment is somapacitan once a week compared to Norditropin® once a day (REAL4); 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03811535. Accessed February 24, 2022.
   Google Scholar
• Chatelain P, Malievskiy O, Radziuk K, et al. A randomized Phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency. J Clin Endocrinol Metab. 2017;102(5):1673–1682. doi:10.1210/jc.2016-3776
   PubMed Web of Science ®Google Scholar
• Gilfoyle D, Mortensen E, Christoffersen ED, Leff JA, Beckert M. A first-in-man phase 1 trial for long-acting TransCon growth hormone. Growth Horm Igf Res. 2018;39:34–39. doi:10.1016/j.ghir.2017.12.002
   PubMed Web of Science ®Google Scholar
• Hoybye C, Pfeiffer AF, Ferone D, et al. A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. Endocr Connect. 2017;6(3):129–138. doi:10.1530/EC-17-0007
   PubMed Web of Science ®Google Scholar
• Thornton PS, Maniatis AK, Aghajanova E, et al. Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: the Phase 3 heiGHt trial. J Clin Endocrinol Metab. 2021;106(11):3184–3195. doi:10.1210/clinem/dgab529
   PubMed Web of Science ®Google Scholar
• Lin Z, Shu AD, Bach M, Miller BS, Rogol AD, Average IGF-1. Prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency. J Endocr Soc. 2022;6(1):bvab168. doi:10.1210/jendso/bvab168
   PubMed Web of Science ®Google Scholar
• Bidlingmaier M, Schilbach K. The use of IGF-I to monitor long-acting growth hormone therapy-timing is an art. J Clin Endocrinol Metab. 2021;106(5):e2367–e2369. doi:10.1210/clinem/dgab016.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A safety, tolerability and efficacy study of TransCon hGH in children with growth hormone deficiency; 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03305016. Accessed February 24, 2022.
   Google Scholar
• ClinicalTrials.gov. A long-term trial investigating safety and efficacy of TransCon hGH in children with growth hormone deficiency who have completed a prior TransCon hGH clinical trial (enliGHten); 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03344458. Accessed February 24, 2022.
   Google Scholar
• Savendahl L, Battelino T, Brod M, et al. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized Phase 2 trial. J Clin Endocrinol Metab. 2020;105(4):01. doi:10.1210/clinem/dgz310
   PubMed Web of Science ®Google Scholar
• Maniatis AK, Nadgir U, Saenger P, et al. OR10-05 Phase 3 FliGHt trial: experience of switching from daily growth hormone therapy to once-weekly TransCon HGH in children with growth hormone deficiency. J Endocr Soc. 2020;4(Supplement_1). doi:10.1210/jendso/bvaa046.963
   Google Scholar
• Maniatis AK, Nadgir U, Hofman P, et al. Poster 154: LONAPEGSOMATROPIN (TransCon hGH) in children with growth hormone deficiency: efficacy and safety of up to 2 years of treatment. Horm Res Paediatr. 2021;94:1–203.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. A trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency (foresiGHt); 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04615273. Accessed February 24, 2022.
   Google Scholar
• Maniatis AK, Casella SJ, Nadgir UM, et al. Efficacy and safety of up to 2 years of treatment with TransCon hGH (Lonapegsomatropin) in treatment-naïve and treatment-experienced children with growth hormone deficiency. J Endocr Soc. 2021;5(Supplement_1):A676–A676. doi:10.1210/jendso/bvab048.1378
   Google Scholar
• Thornton P, Hofman P, Maniatis AK, et al. TransCon growth hormone in the treatment of pediatric growth hormone deficiency results of the Phase 3 HeiGHt trial; 2019. https://ascendispharma.com/wp-content/uploads/ENDO-2019-heiGHt-Trial-Presentation.pdf. Accessed July 8, 2019.
   Google Scholar
• Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1–P9. doi:10.1530/EJE-15-0873
   PubMed Web of Science ®Google Scholar
• Christiansen JS, Backeljauw PF, Bidlingmaier M, et al. Growth hormone research society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1–C8. doi:10.1530/EJE-16-0111
   PubMed Web of Science ®Google Scholar
• Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res. 2004;62(Suppl 1):59–65. doi:10.1159/000080760
   PubMedGoogle Scholar
• Cohen P, Rogol AD, Howard CP, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007;92(7):2480–2486. doi:10.1210/jc.2007-0204
   PubMed Web of Science ®Google Scholar
• Ascendis. SKYTROFA™ (lonapegsomatropin-tcgd) for injection, for subcutaneous use; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf. Accessed February 12, 2022.
   Google Scholar
• Walsh K, Campbell D, Permuy J, et al. Introduction of a novel GH auto-injector for once-weekly administration of TransCon hGH. Pediatric Endocrine Nurses Society 2021 National Conference; 2020; Virtual.
   Google Scholar
• Raman S, Grimberg A, Waguespack SG, et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy–A report from the pediatric endocrine society drug and therapeutics committee. J Clin Endocrinol Metab. 2015;100(6):2192–2203. doi:10.1210/jc.2015-1002
   PubMed Web of Science ®Google Scholar
• Allen DB, Merchant N, Miller BS, Backeljauw PF. Evolution and future of growth plate therapeutics. Horm Res Paediatr. 2021;94(9–10):319–332. doi:10.1159/000520812
   PubMed Web of Science ®Google Scholar
• Djambas Khayat C. Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. J Blood Med. 2016;7:275–282. doi:10.2147/JBM.S84597
   PubMed Web of Science ®Google Scholar
• Jose B, Tahrani AA, Piya MK, Barnett AH. Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Prefer Adherence. 2010;4:313–324.
   PubMed Web of Science ®Google Scholar
• Li A, Goodfriend C, Sokol J, Kruse-Jarres R. Patterns and predictors of emicizumab adherence in people with hemophilia. Blood. 2019;134(Supplement_1):2178. doi:10.1182/blood-2019-128083
   Web of Science ®Google Scholar
• Qiao Q, Ouwens MJ, Grandy S, Johnsson K, Kostev K. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes Targets Ther. 2016;9:201–205. doi:10.2147/DMSO.S99732
   PubMed Web of Science ®Google Scholar
• Miller BS, Rosenfeld RG. Monitoring rhGH safety: rhGH registries, SAGhE and future needs. Pediatr Endocrinol Rev. 2018;16(Suppl 1):150–161. doi:10.17458/per.vol16.2018.mr.monitoringrhghsafety
   PubMedGoogle Scholar
• Savendahl L, Cooke R, Tidblad A, et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol. 2020;8(8):683–692. doi:10.1016/S2213-8587(20)30163-7
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Cooke R, Albertsson-Wikland K, et al. Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr. 2015;84(3):172–183. doi:10.1159/000435856
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Cooke R, Beckers D, et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab. 2017;102(5):1661–1672. doi:10.1210/jc.2016-2046
   PubMed Web of Science ®Google Scholar